source
- Experts warn FDA against approving Grail’s ineffective multicancer blood testPhysician and cancer‑screening researcher H. Gilbert Welch argues that the FDA should not greenlight Grail’s multicancer blood test, noting the company’s trial of 140,000 participants used a weak s…
- Lycia Therapeutics files for IPO to fund antibody degrader platformLycia Therapeutics, a protein‑degradation startup built on research from Nobel laureate Carolyn Bertozzi, announced it has filed for an initial public offering. The filing is intended to raise cap…